TG Therapeutics downgraded to Buy after 17% rally; Briumvi trials and financial moves support growth.

TG Therapeutics was downgraded from Strong Buy to Buy following a 17% stock rally, reflecting a more balanced valuation. Its Briumvi IV treatment continues to gain market share in multiple sclerosis, while the subcutaneous (SC) version's trial is fully enrolled, potentially doubling the market size. The company projects conservative 2026 U.S. net revenue of $825–$850 million for Briumvi and maintains strict operating expense targets. Financially, TG Therapeutics secured a $750 million term loan, expanded share buybacks, and avoided equity dilution to support ongoing growth initiatives.